Biotech company Aldea has raised $24m in a series B round featuring WuXi PharmaTech and Rusnano, which will support the treatment of patients with acute alcohol intoxication.
US-based novel therapeutics developer Aldea Pharmaceuticals has received $24m in a series B round that included participation from WuXi PharmaTech Corporate Ventures, the corporate venturing unit of biopharmaceutical company WuXi Pharmatech.
RusnanoMedInvest, a subsidiary of the Russian state-run investment firm Rusnano, and venture capital firms Canaan Partners and Correlation Ventures also took part in the round.
The capital will be used to advance the testing of Aldea’s AD-6626, a drug candidate for the treatment of acute alcohol intoxication, into…
